Fenofibrate as an early treatment option in newly onset type 1 diabetes

In this study, we will investigate the antidiabetic effects of the drug fenofibrate in newly onset T1D. The study is designed as a randomized, double-blinded placebo-controlled clinical trial with 58 newly diagnosed T1D patients.    


Type 1 diabetes (T1D) is a severe autoimmune disease characterized by destruction of insulin-producing pancreatic beta-cells, leading to a lifelong dependence of injected insulin; an extremely demanding therapy associated with severe side effects, highlighting the need for new treatment strategies.

Description

Fenofibrate is a well-known drug that has been used in the treatment of hypercholesterolemia for decades. However, resent studies indicate a novel antidiabetic effect in newly onset T1D. Animal studies has shown that oral treatment with fenofibrate can prevent and even revers diabetes in Non-obese diabetic mice, which otherwise develop autoimmune diabetes spontaneously. Therefore, we hypothesize that fenofibrate can prevent beta-cell destruction in patients newly diagnosed with T1D  

Aim:

The aim of this study is to investigate if oral treatment with fenofibrate for 12 months can stop disease progression and improve residual insulin production in patients with newly onset T1D

Collaborators 

J. Johannesen: Division of Paediatric and Adolescent Medicine, Herlev Hospital
K. Buschard:  Rigshospitalet







Responsible editor